Insights into Coherus Oncology's Financial Performance and Its Competitive Landscape

Coherus Oncology, Inc. (CHRS) has a significantly negative Return on Invested Capital (ROIC) of -117.17%, indicating challenges in generating returns on its invested capital.Atara Biotherapeutics, Inc. (ATRA) showcases a strong financial position with a ROIC of 36.19% and a Weighted Average Cost of Capital (WACC) of 6.36%, highlighting efficient capital utilization.Comparatively, companies like FibroGen, Inc. (FGEN) and MacroGenics, Inc. (MGNX) also face challenges with negative ROIC to WACC ratios, indicat ...